Milan (Italy), April 21st – 23rd, 2016
Organized by:
Center for the Study of Atherosclerosis
and Center of Epidemiology and Preventive Pharmacology, Department of Pharmacological and Biomolecular Sciences University of Milan (Italy)
Promoted by:
Fondazione Internazionale Menarini
In recent years, we have witnessed an explosion of the information derived from genetics and biology that has paved the way for better understanding of physiology and pathology for a number of diseases.
The area of dyslipidemias is not an exception: with the advent of new technologies for studies of the genetic code, the knowledge of human genetics of lipoproteins has improved tremendously.
Translational medicine and understanding of the genetic cause of a condition is crucial for an adequate care. Furthermore, the study of human DNA and disease causing mutation has led to new drug discovery to treat dyslipidemia.
This meeting will address these new frontiers as well as how this new knowledge affects our clinical approach to the control of dyslipidemias and ultimately of cardiovascular disease.
Top scientists from the field will address these issues with a series of lectures that will benefit not only physicians, but also professionals in pharmacology, genetics or biology with an interest in this area.
Prof. Alberico L. Catapano President of the Meeting
Interview with:
Jan BOREN
Wallenberg Laboratory
Sahlgrenska Academy at Göteborg University
Sahlgrenska University Hospital
Göteborg (Sweden)
- What is the role of LDL cholesterol in cardiovascular diseases?
INTERVIEW WITH:
Brian A. FERENCE
Division of Cardiovascular Medicine
Cardiovascular Genomic Research Center
Division of Translational Research and Clinical Epidemiology (TRaCE)
Wayne State University School of Medicine
Detroit (Michigan, USA)
- Genetics and cardiovascular diseases: where we stand?
- Where we are going to in the future?
- Is the knowledge of genetics of cholesterol improved?
- Will our knowledges change the approach in the control of cholesterol?
INTERVIEW WITH:
Ian GRAHAM
Charlemont Cardiology
Charlemont Clinic
Dublin (Ireland)
- What’s the contribution of plasma lipids in the epidemiological approach of cardiovascular diseases?
- What’s the role of lifestyle, obesity and diabetes?
INTERVIEW WITH:
Jennifer G. ROBINSON
Departments of Epidemiology & Medicine
Prevention Intervention Center
Department of Epidemiology
Iowa City (IA, USA)
- Early treatment or intensive therapy to reduce the levels of lipids?
INTERVIEW WITH:
Erik S.G. STROES
Department of Vascular Medicine
Academic Medical Center
Amsterdam (The Netherlands)
- What’s the role of lipids and lipoproteins in the epigenetics of cardiovascular diseases?
- Lower is better: is it still a valid guideline?
INTERVIEW WITH:
Arnold von ECKARDSTEIN
Institute of Linical Chemistry
University Hospital Zürich
Zürich (Switzerland)
- What’s the role of HDL cholesterol on cardiovascular diseases?
- Do we have therapies to improve the levels of HDL cholesterol?
- Is lifestyle the better therapy?
